Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults
© 2016 Wolters Kluwer Health, Inc. All rights reserved. HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a com...
Saved in:
Main Authors: | Cressey T., Hazra R., Wiznia A., Foca M., Jean-Philippe P., Graham B., King J., Britto P., Carey V., Acosta E., Yogev R. |
---|---|
Format: | Journal |
Published: |
2017
|
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84984700603&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/41295 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults
by: Tim R. Cressey, et al.
Published: (2018) -
Rilpivirine pharmacokinetics without and with darunavir/ritonavir once daily in adolescents and young adults
by: Foca M., et al.
Published: (2017) -
Rilpivirine pharmacokinetics without and with darunavir/ritonavir once daily in adolescents and young adults
by: Marc Foca, et al.
Published: (2018) -
Pharmacokinetics of once-daily darunavir/ ritonavir with and without etravirine in human immunodeficiency virus-infected children, adolescents, and young adults
by: Larson K., et al.
Published: (2017) -
Pharmacokinetics of darunavir/ritonavir with etravirine both twice daily in human immunodeficiency virus-infected adolescents and young adults
by: Tim R. Cressey, et al.
Published: (2018)